tirzepatide patent expiry 2036 eli lilly Lilly's showed positive results in late-stage trial as treatment for heart failure Republican Administration Maintains Exclusivity Stance

Here's what we'll cover Key takeaways Zepbound (tirzepatide) is a dual-action GLP-1/GIP receptor agonist that can help promote weight loss and treat obstructive sleep apnea in people with obesity

FDA-approved Mounjaro and Zepbound: up to 21 days at room temperature below 30 degrees Celsius (86 degrees Fahrenheit)

Retatrutide is not authorized by Health Canada or the FDA and remains an investigational drug under Phase 3 clinical evaluation

Semaglutide $115/week for any dose Weekly visits for expert guidance

Coverage varies by insurance plan

Its designed for adults with obesity or overweight issues, aiming to enhance fullness from less food